Retrospective efficacy analysis of immune checkpoint inhibitors in patients with EGFR‐mutated non‐small cell lung cancer
| العنوان: | Retrospective efficacy analysis of immune checkpoint inhibitors in patients with EGFR‐mutated non‐small cell lung cancer |
|---|---|
| المؤلفون: | Shinsuke Shiotsu, Yusuke Chihara, Akihiro Yoshimura, Yutaka Kubota, Koichi Takayama, Nobuyo Tamiya, Yoshiko Kaneko, Takayuki Takeda, Keiko Tanimura, Soichi Hirai, Tadaaki Yamada, Taishi Harada, Kazuki Hirose, Toshiaki Kikuchi, Junji Uchino, Satoshi Watanabe, Yuki Katayama |
| المصدر: | Cancer Medicine, Vol 8, Iss 4, Pp 1521-1529 (2019) Cancer Medicine |
| بيانات النشر: | Wiley, 2019. |
| سنة النشر: | 2019 |
| مصطلحات موضوعية: | 0301 basic medicine, Oncology, Male, Cancer Research, Lung Neoplasms, Immune checkpoint inhibitors, medicine.medical_treatment, immunology, T790M, 0302 clinical medicine, Antineoplastic Agents, Immunological, Carcinoma, Non-Small-Cell Lung, Epidermal growth factor receptor, Original Research, Aged, 80 and over, biology, Kinase, Middle Aged, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, ErbB Receptors, Nivolumab, Treatment Outcome, 030220 oncology & carcinogenesis, Biomarker (medicine), biomarker, Female, Non small cell, Immunotherapy, Adult, non‐small cell lung cancer, medicine.medical_specialty, Antibodies, Monoclonal, Humanized, lcsh:RC254-282, 03 medical and health sciences, Internal medicine, medicine, Humans, Radiology, Nuclear Medicine and imaging, Lung cancer, Aged, Retrospective Studies, business.industry, Clinical Cancer Research, medicine.disease, Survival Analysis, respiratory tract diseases, 030104 developmental biology, Drug Resistance, Neoplasm, Mutation, biology.protein, EGFR mutation, business |
| الوصف: | Background Treatment with epidermal growth factor receptor (EGFR)‐tyrosine kinase inhibitors (TKIs) leads to initial response in most patients with EGFR‐mutated non‐small cell lung cancer (NSCLC). In contrast, little is known of the subpopulation of patients with NSCLC with EGFR mutations who exhibit clinical outcomes that require treatment with immune checkpoint inhibitors (ICIs). Therefore, to identify eligible cases to treat with ICIs, we retrospectively analyzed the correlation between clinical features and the efficacy of ICIs in patients with EGFR mutations. Patients and Methods We retrospectively analyzed patients with advanced NSCLC harboring EGFR mutations who were treated with ICIs after developing resistance to EGFR‐TKIs between February 2016 and April 2018 at 6 institutions in Japan. The association between clinical outcomes and the efficacy of ICIs was investigated. Results We enrolled 27 patients who harbored EGFR‐activating mutations. The objective response and disease control rates were higher in patients with uncommon EGFR mutations than in those with common EGFR mutations (71% vs 35.7% and 57% vs 7%, P = 0.14 and P |
| اللغة: | English |
| تدمد: | 2045-7634 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5d5b4bcf9b850b44ed1afbab6ce8bae2Test https://doaj.org/article/6018c2c492604e2d9a105d52498c1361Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....5d5b4bcf9b850b44ed1afbab6ce8bae2 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 20457634 |
|---|